Q: What is Komzifti used for?

Komzifti is used to treat chronic hepatitis C virus infection .

Q: How does Komzifti work?

Mechanism of Action Komzifti belongs to a class of medications known as menin-KMT2A inhibitors. It is specifically designed to target the underlying biological processes that drive certain types of acute myeloid leukemia (AML). In some forms of AML, such as those with a KMT2A rearrangement or an NPM1 mutation, two proteins called menin and KMT2A bind together. This pairing creates a complex that activates specific genes, signaling the leukemia cells to grow, divide, and survive uncontrollably. Komzifti works through the following process: Binding to menin: The medication attaches itself to the menin protein. Disrupting the complex: By binding to menin, the drug prevents the KMT2A protein from connecting with it. Interrupting cancer signals: When these two proteins are blocked from interacting, the genetic signals that tell the leukemia cells to multiply are turned off. By breaking this protein connection, Komzifti helps to slow or stop the progression of the cancer and may lead to the death of the leukemia cells.

Q: What are the active ingredients in Komzifti?

The active ingredient in Komzifti is ziftomenib .

Q: What are the side effects of Komzifti?

Common side effects of Komzifti may include not FDA approved . There is no reliable, publicly available data defining common side effects. Always consult with a healthcare professional about potential side effects.

Q: What drug class is Komzifti?

Komzifti belongs to the monoclonal antibody combination drug class.

Q: What is the dosage of Komzifti and how do I take it?

How to Take Komzifti is a tablet taken by mouth once daily. It should be swallowed whole with a glass of water and should not be crushed, chewed, or broken. You may take this medication with or without food, but it is important to take it at approximately the same time every day to maintain consistent levels in your body. Missed Dose If you miss a dose of Komzifti, take it as soon as you remember on the same day. If you do not remember until the following day, skip the missed dose and take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose. Vomiting If you vomit after taking a dose of Komzifti, do not take an additional dose to replace it. Simply wait and take your next scheduled dose at the usual time the next day.

Q: Is Komzifti safe during pregnancy and breastfeeding?

Pregnancy and Contraception Komzifti can cause harm to a developing fetus. Healthcare providers typically perform a pregnancy test on females of reproductive potential before starting treatment to confirm they are not pregnant. Effective birth control is necessary for those taking this medication: Females: Use effective contraception during treatment and for 1 month after the last dose. Males: If you have a female partner who can become pregnant, use effective contraception during treatment and for 1 month after the last dose. Breastfeeding It is unknown if Komzifti passes into breast milk. Due to the potential for serious adverse reactions in a breastfed child, it is recommended to avoid breastfeeding during treatment and for 1 week after the final dose. Individuals should discuss their options and any concerns with their healthcare provider before starting or continuing treatment.

Q: What is the FDA approval status of Komzifti?

FDA Approval Status The U.S. Food and Drug Administration (FDA) approved Komzifti in January 2025. It is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) that has a nucleophosmin 1 (NPM1) mutation, as detected by an FDA-approved test. Boxed Warning Komzifti includes a Boxed Warning, which is the FDA’s most serious type of warning, for a condition called differentiation syndrome. This condition can be fatal if not treated. It occurs when leukemia cells release chemicals into the blood, potentially causing symptoms such as: Fever and cough Trouble breathing Rash Decreased urination Rapid weight gain or swelling in the arms, legs, or neck Healthcare providers monitor patients closely for these symptoms, particularly during the first cycle of treatment, and may interrupt or stop the medication if the syndrome occurs. Regulatory Background The approval of Komzifti was based on clinical evidence demonstrating its effectiveness in achieving complete remission in patients with the NPM1 mutation who had not responded to or had relapsed after previous treatments. It is classified as a menin inhibitor, representing a specific class of targeted therapy for this patient population.

Question 1

What is Komzifti?

Accepted Answer

Komzifti is a medication that contains the active ingredient soquelitinib. It belongs to a class of drugs known as interleukin-2-inducible T-cell kinase (ITK) inhibitors.

This therapy works by targeting and blocking the ITK protein found in certain immune cells. By interfering with this protein's function, the medication helps to control signaling pathways that are involved in the growth and survival of cancer cells.

Question 2

What is Komzifti used for?

Accepted Answer

Komzifti is used to treat chronic hepatitis C virus infection.

Question 3

How does Komzifti work?

Accepted Answer

Mechanism of Action

Komzifti belongs to a class of medications known as menin-KMT2A inhibitors. It is specifically designed to target the underlying biological processes that drive certain types of acute myeloid leukemia (AML).

In some forms of AML, such as those with a KMT2A rearrangement or an NPM1 mutation, two proteins called menin and KMT2A bind together. This pairing creates a complex that activates specific genes, signaling the leukemia cells to grow, divide, and survive uncontrollably.

Komzifti works through the following process:

Binding to menin: The medication attaches itself to the menin protein.
Disrupting the complex: By binding to menin, the drug prevents the KMT2A protein from connecting with it.
Interrupting cancer signals: When these two proteins are blocked from interacting, the genetic signals that tell the leukemia cells to multiply are turned off.

By breaking this protein connection, Komzifti helps to slow or stop the progression of the cancer and may lead to the death of the leukemia cells.

Question 4

What are the active ingredients in Komzifti?

Accepted Answer

The active ingredient in Komzifti is ziftomenib.

Question 5

What are the side effects of Komzifti?

Accepted Answer

Common side effects of Komzifti may include not FDA approved. There is no reliable, publicly available data defining common side effects. Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Komzifti?

Accepted Answer

Komzifti belongs to the monoclonal antibody combination drug class.

Question 7

What is the dosage of Komzifti and how do I take it?

Accepted Answer

How to Take

Komzifti is a tablet taken by mouth once daily. It should be swallowed whole with a glass of water and should not be crushed, chewed, or broken. You may take this medication with or without food, but it is important to take it at approximately the same time every day to maintain consistent levels in your body.

Missed Dose

If you miss a dose of Komzifti, take it as soon as you remember on the same day. If you do not remember until the following day, skip the missed dose and take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.

Vomiting

If you vomit after taking a dose of Komzifti, do not take an additional dose to replace it. Simply wait and take your next scheduled dose at the usual time the next day.

Question 8

Is Komzifti safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy and Contraception

Komzifti can cause harm to a developing fetus. Healthcare providers typically perform a pregnancy test on females of reproductive potential before starting treatment to confirm they are not pregnant.

Effective birth control is necessary for those taking this medication:

Females: Use effective contraception during treatment and for 1 month after the last dose.
Males: If you have a female partner who can become pregnant, use effective contraception during treatment and for 1 month after the last dose.

Breastfeeding

It is unknown if Komzifti passes into breast milk. Due to the potential for serious adverse reactions in a breastfed child, it is recommended to avoid breastfeeding during treatment and for 1 week after the final dose.

Individuals should discuss their options and any concerns with their healthcare provider before starting or continuing treatment.

Question 9

What forms and strengths does Komzifti come in?

Accepted Answer

Komzifti is supplied as a tablet for oral administration. It is intended to be swallowed whole and should not be crushed, chewed, or broken.

Oral Tablet

Question 10

What is the FDA approval status of Komzifti?

Accepted Answer

FDA Approval Status

The U.S. Food and Drug Administration (FDA) approved Komzifti in January 2025. It is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) that has a nucleophosmin 1 (NPM1) mutation, as detected by an FDA-approved test.

Boxed Warning

Komzifti includes a Boxed Warning, which is the FDA’s most serious type of warning, for a condition called differentiation syndrome. This condition can be fatal if not treated. It occurs when leukemia cells release chemicals into the blood, potentially causing symptoms such as:

Fever and cough
Trouble breathing
Rash
Decreased urination
Rapid weight gain or swelling in the arms, legs, or neck

Healthcare providers monitor patients closely for these symptoms, particularly during the first cycle of treatment, and may interrupt or stop the medication if the syndrome occurs.

Regulatory Background

The approval of Komzifti was based on clinical evidence demonstrating its effectiveness in achieving complete remission in patients with the NPM1 mutation who had not responded to or had relapsed after previous treatments. It is classified as a menin inhibitor, representing a specific class of targeted therapy for this patient population.

Question 11

What should I know about Komzifti and cost?

Accepted Answer

Insurance and Pharmacy Factors

The price you pay for Komzifti is largely determined by your health insurance plan. Most insurance providers, including Medicare, cover oncology treatments, but your specific out-of-pocket costs will depend on your plan's formulary, deductible, and copayment or coinsurance requirements.

Komzifti is a specialty medication and is typically dispensed through specialty pharmacies rather than standard retail pharmacies. These pharmacies can provide specific pricing information and help coordinate delivery of the medication.

Financial Assistance

There may be options available to help manage the cost of treatment:

Patient Assistance Programs: These programs are often available for patients who are uninsured or have limited insurance coverage to help them access their medication.
Copay Support: Eligible patients with commercial insurance may be able to use copay cards or savings programs provided by the manufacturer to reduce their out-of-pocket expenses.

To determine the exact cost, it is best to contact your insurance provider or speak with your healthcare team about available support services and specialty pharmacy options.

Komzifti

📋Overview

How It Works

Uses

Active Ingredients

Common Side Effects

Warnings & Precautions

Dosage

Pregnancy & Breastfeeding

Frequently Asked Questions

Found an Error?

Find Discounts for Komzifti

Hospitals.net Disclosure